4//SEC Filing
Lefebvre Eric 4
Accession 0000950170-24-035468
CIK 0001042074other
Filed
Mar 21, 8:00 PM ET
Accepted
Mar 22, 5:05 PM ET
Size
10.4 KB
Accession
0000950170-24-035468
Insider Transaction Report
Form 4
Lefebvre Eric
Director
Transactions
- Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−25,000→ 0 totalExercise: $7.80Exp: 2033-01-24→ Common Stock (25,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−115,000→ 0 totalExercise: $3.21Exp: 2032-03-20→ Common Stock (115,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2024-03-22−14,010→ 0 totalExercise: $22.85Exp: 2034-01-23→ Common Stock (14,010 underlying)
Footnotes (1)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Documents
Issuer
CymaBay Therapeutics, Inc.
CIK 0001042074
Entity typeother
Related Parties
1- filerCIK 0001614741
Filing Metadata
- Form type
- 4
- Filed
- Mar 21, 8:00 PM ET
- Accepted
- Mar 22, 5:05 PM ET
- Size
- 10.4 KB